Drugs that lengthen mouse lives helped heavy male mice far more than light ones

A reanalysis of nearly 34,000 mice from the largest US drug-testing programme for aging found that lifespan gains were about three times larger in the heaviest males than in the lightest. Part of what looks like slowed aging may be the rescue of overfed lab mice. A preprint, in mice only.

Several drugs discussed as possible ways to slow aging, such as rapamycin and the diabetes drug acarbose, have been tested in the Interventions Testing Program (ITP) of the US National Institute on Aging. It gives compounds to large groups of genetically varied mice at three separate labs and checks whether they live longer than untreated mice. It is widely regarded as the most rigorous test of its kind.

But lab mice usually have food available all day and little to do. Many grow heavy and develop problems like those of overweight people, such as poor control of blood sugar. A drug could lengthen their lives in two ways: by slowing aging itself, or by undoing the harm of overfeeding. A new analysis, posted as a preprint that has not yet been peer-reviewed, tries to tell the two apart.

What they did

The researchers did not run new experiments. They took the ITP's published records of body weight and lifespan for 33,780 mice: 17,943 males in 92 experiments and 15,837 females in 88 experiments, from 17 yearly batches of mice. In each experiment, they asked whether the drug's benefit was larger in mice that were heavier than their peers in the same experiment.

To make sure the drugs themselves had not changed the weights, a key analysis used only weights taken before dosing began. They also compared the ITP's untreated mice with those in other published mouse lifespan studies.

What they found

  • Heavier males gained more. In 30 experiments with drugs that lowered body weight, the median lifespan gain was 6.2% in the lightest quarter of male mice and 20.2% in the heaviest quarter.
  • Mostly because heavy untreated mice died young. From lightest to heaviest quarter, untreated males lost 217 days of median lifespan, treated males 136 days. Even with treatment, the heaviest mice still died earlier than the lightest untreated ones. By day 500, 27.6% of the heaviest untreated males had died, against 6.3% of the lightest.
  • Not one odd drug. The same pattern held for 13 of 14 compounds, including acarbose, rapamycin, the diabetes drug canagliflozin and the hormone 17α-estradiol. Drugs that did not lower weight showed no clear pattern.
  • Weight gained as an adult was what counted. Weight at puberty did not matter once adult weight was known.
  • Some drugs kept a benefit in light mice. Acarbose, rapamycin, canagliflozin and 17α-estradiol still added 6–8% to median lifespan in the lightest quarter (against 21–25% in the heaviest). Others, including resveratrol and fisetin, showed no gain in light mice, though most were tested only once.
  • Females were different, but probably because of the ITP itself. In ITP females, weight barely changed how well drugs worked. But untreated ITP females lived unusually long: none of the female control groups from other studies that the team collected reached their median lifespan, leaving less early death for drugs to prevent. In two other mouse groups, heavier females did die sooner, much like ITP males.

What to keep in mind

  • Mice only. The authors stress that mouse weight cannot be mapped directly onto human body mass index, and nothing here was tested in people.
  • Even the "light" mice were heavy. The lightest quarter of males still weighed about 14% more than the average of 27 lab mouse strains at a similar age, and more than mice of the same type kept on a controlled diet. So it remains unclear how well any drug would work against truly healthy controls.
  • A reanalysis. The study re-examines existing data and shows associations within it; it did not test drugs against leaner mice directly. The authors call for experiments that do just that.
  • Small numbers per drug. Most compounds came from a single experiment.
  • Not yet peer-reviewed.

Why it matters

The ITP is the reference point for claims that a drug slows aging. This analysis suggests that much of the gain it records, at least in males, may come from rescuing mice made unhealthy by unlimited food and little exercise. In the authors' words, the benefits "may thus be less apparent in metabolically healthier mice or humans". It does not mean the drugs do nothing: several kept a smaller benefit even in the lightest mice. But it is a reason to be cautious about mouse lifespan headlines, including for new appetite-suppressing drugs now entering aging research.